Lymphoma News

Topical ruxolitinib cream significantly reduced skin manifestations caused by cutaneous graft-versus-host disease compared with vehicle cream, results from a randomized phase 2 study showed.

Individuals with relapsed or refractory lymphoma who received chimeric antigen receptor T-cell therapy experienced a wide range of adverse events compared with those who received other treatments, study results showed.

In this video, Tycel Phillips, MD, discusses conditions common in patients with DLBCL.

In this video, Tycel Phillips, MD, discusses treatment options available to patients with DLBCL.

In this video, Tycel Phillips, MD, discusses high-risk subtypes of DLBCL and how to manage these cases.

In this video, Tycel Phillips, MD, discusses treatment options available to patients with DLBCL.

In this video, Tycel Phillips, MD, discusses challenges in diagnosing DLBCL.

More than 130,000 cancer cases went undiagnosed during the first 10 months of the COVID-19 pandemic, researchers estimated in a cross-sectional analysis published in JAMA Oncology.

Limiting eligibility criteria, recruiting trusted community messengers and reducing financial burdens can help improve diversity of clinical trial enrollees, a panel of professionals said during a Friends of Cancer Research webinar.

A COVID-19 diagnosis led to a delay in receiving chemotherapy among younger patients with acute lymphoblastic leukemia or lymphoblastic lymphoma, results from a retrospective analysis published in JAMA Network Open showed.